SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...

I vividly remember the day I found out I was pregnant with my daughter. I was beaming from ear to ear, excited to finally become a mom. I expected the weight gain, stretch marks, swollen ankles and ...

Acne is almost a teenage rite of passage, but that doesn’t mean children should be told to “wait it out.” Adolescence brings a surge of hormones that increase oil production, making skin more ...

This is a review article written after watching the broadcast. On ‘Sixth Sense: City Tour 2’, Yoo Jae-suk mentioned Jee Seok-jin’s columella reduction surgery. Aired on the 27th, tvN’s ‘Sixth Sense: ...

[OSEN=Park Geun-hee, reporter] In ‘Sixth Sense: City Tour 2,’ Kim Won-hoon drew laughter as soon as he appeared, with his red nose caught by Yoo Jae-suk’s sharp gaze. Broadcasted on the afternoon of ...

State Dept. Raises Alarm on Mass Migration Scientists Studied 'SuperAgers' For 25 Years And Found That They All Have This 1 Habit In Common Thanksgiving Day in America The 34-Year Experiment That ...

This article is part of Nature Outlook: Skin, an editorially independent supplement produced with financial support from LEO Pharma. About this content. Acne has long been dismissed as an unfortunate ...

Acne has long been dismissed as an unfortunate cosmetic issue — a rite of passage that is ultimately of little importance. But that attitude is changing. Many scientists now accept that acne is an ...

Watch as we handle the venomous aftermath of a centipede bite—an intense extraction you won’t forget! Donald Trump's approval rating suddenly shifts with Gen Z Here’s Why You May See Turquoise Arches ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...